INNO.CN - InnoCan Pharma Corporation

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.2100
+0.0050 (+2.44%)
At close: 10:49AM EDT
Stock chart is not supported by your current browser
Previous Close0.2050
Open0.2100
Bid0.2050 x N/A
Ask0.2200 x N/A
Day's Range0.2000 - 0.2100
52 Week Range0.0500 - 0.4000
Volume97,500
Avg. Volume550,090
Market Cap30.212M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0260
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Innocan's Over-The-Counter Pain Relief Spray Receives FDA's Technical Validation for Marketing in the USA
    Newsfile

    Innocan's Over-The-Counter Pain Relief Spray Receives FDA's Technical Validation for Marketing in the USA

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 13, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it has received notice from the FDA that Innocan's over-the-counter Relief & Go Pain Relief spray product has successfully received technical validation and approval to commence marketing in the USA. Innocan's pain relief formulation contains a combination of Magnesium oil, Methyl salicylate, Menthol and CBD. The Relief ...

  • InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments
    Newsfile

    InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments

    Herzeliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 9, 2020) - InnoCan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce its collaboration with Recipharm, Israel to synthesize and analyze cannabinoid loaded exosomes.Recipharm unites more than 30 facilities across 10 different countries offering a range of services, mainly in two different operating areas, pharmaceutical development services and manufacturing services. Recipharm offers seamless tech transfer from Recipharm development facilities ...

  • Innocan Pharma's Corporate Update
    Newsfile

    Innocan Pharma's Corporate Update

    Calgary, Alberta--(Newsfile Corp. - July 2, 2020) - Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan") announced today that Mr. Bill Macdonald has resigned as a member of the Company's board of directors effective June 29, 2020. The Company wishes to thank Mr. Macdonald for all his efforts and supporting the Company since the IPO in September 2019. The Company also announced today that it reached an agreement with a former ...

  • InnoCan Pharma Announces the Successful Completion of an Independent Clinical Study Demonstrating Safety and Skin Tolerance of Its CBD Derma Cosmetic Line
    Newsfile

    InnoCan Pharma Announces the Successful Completion of an Independent Clinical Study Demonstrating Safety and Skin Tolerance of Its CBD Derma Cosmetic Line

    Herzeliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 26, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce the results from the first Dermal clinical study of Relief & Go ™ and Shir ™ product lines. The double blinded randomized controlled study assessed the tolerance degree of the Company's CBD Topicals products and demonstrated the products to be non-irritating to the skin. InnoCan's contract manufacturer for ...

  • Innocan Pharma Announces Mackie Research's Institutional Sales Group Issues Enterprise Publication on the Company
    Newsfile

    Innocan Pharma Announces Mackie Research's Institutional Sales Group Issues Enterprise Publication on the Company

    Herzeliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 22, 2020) -  Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that Mackie Research Capital Corporation's institutional sales group has issued an Enterprise publication on the Company. The Enterprise publication provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into action. This publication is based ...

  • InnoCan Signs Letter of Intent with Tamar to Distribute and Supply CBD "API" for use in InnoCan's Research Projects
    Newsfile

    InnoCan Signs Letter of Intent with Tamar to Distribute and Supply CBD "API" for use in InnoCan's Research Projects

    Herzeliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 17, 2020) - InnoCan Pharma Corporation (CSE: INNO) (FSE: IP4) ("InnoCan" or the "Company") announced that it has signed a non-binding Letter of Intent with its major shareholder Tamar Innovest Ltd (formerly Solsken Ltd) ("Tamar"), a wholly owned subsidiary of Tamar Technologies Limited ("Tamar Tech") whereby, subject to the entering into of a formal agreement between the parties, Tamar will distributenaturally sourced CBD, ...

  • Innocan Pharma Announces Closing of $5.1 Million Prospectus Offering of Units
    Newsfile

    Innocan Pharma Announces Closing of $5.1 Million Prospectus Offering of Units

    Toronto, Ontario--(Newsfile Corp. - June 10, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce the closing of its marketed short form prospectus offering pursuant to which the Company issued 28,423,943 units of the Company (the "Units") at a price of $0.18 per Unit for gross proceeds of $5,116,309.74 (the "Offering"). The Offering was led by Mackie Research Capital Corporation, as sole bookrunner, and Canaccord Genuity ...

  • InnoCan Pharma Announced the Commencement of its Derma CBD Line Commercial Production in Portugal
    Newsfile

    InnoCan Pharma Announced the Commencement of its Derma CBD Line Commercial Production in Portugal

    Calgary, Alberta and Tel Aviv, Israel--(Newsfile Corp. - June 5, 2020) - InnoCan Pharma (CSE: INNO) ("InnoCan" or the "Company") is pleased to announce the commencement of commercial production if Derma CBD line in Portugal. The first product which are currently manufactured is The Patent Pending Relief & Go CBD Spray, one of InnoCan's flagship products, developed by chief technology officer Nir Avram.Nir Avram the company's CTO T commented: "The patent pending ...

  • Innocan Pharma Amends Terms of Marketed Short Form Prospectus Offering of Units
    Newsfile

    Innocan Pharma Amends Terms of Marketed Short Form Prospectus Offering of Units

    Toronto, Ontario--(Newsfile Corp. - June 2, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), announces that it has amended certain terms of its marketed offering of units of the Company (the "Units"), that was previously announced on May 11, 2020 and May 14, 2020 (the "Offering"). Pursuant to the amended terms, the Offering of Units will be conducted at a price of $0.18 per Unit for minimum gross proceeds ...

  • Innocan Pharma Announces Patent Application for Novel Cannabis-Based Psoriasis Treatment
    Newsfile

    Innocan Pharma Announces Patent Application for Novel Cannabis-Based Psoriasis Treatment

    Calgary, Alberta and Tel Aviv, Israel--(Newsfile Corp. - May 28, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly-owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel"), filed an international patent application for a novel cannabis-based psoriasis treatment. This patent application makes claim of a topical pharmaceutical composition used to treat the symptoms of itching and inflammation associated with psoriasis."The global psoriasis drugs market is ...

  • InnoCan Pharma Enters into Letter of Intent to Develop and Produce Exosomes for Use in its CBD-Loaded Exosome (CLX) Treatments
    Newsfile

    InnoCan Pharma Enters into Letter of Intent to Develop and Produce Exosomes for Use in its CBD-Loaded Exosome (CLX) Treatments

    Calgary, Alberta and Tel Aviv, Israel--(Newsfile Corp. - May 22, 2020) - InnoCan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly-owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel"), has entered into a letter of intent ("LOI") with Adva Biotechnology Ltd. ("ADVA") dated May 21, 2020. The LOI sets out the indicative terms of an exosome production and development agreement (the "Exosome Production Agreement") which the parties ...

  • Innocan Pharma Announces Pricing of Marketed Short Form Prospectus Offering of Units
    Newsfile

    Innocan Pharma Announces Pricing of Marketed Short Form Prospectus Offering of Units

    Toronto, Ontario--(Newsfile Corp. - May 14, 2020) -  Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it has priced its previously announced marketed offering of units of the Company (the "Units") at a price of $0.20 per Unit (the "Offering Price") to raise aggregate gross proceeds of up to $10,000,000 (the "Offering"). Each Unit shall be comprised of one common share of the Company (a "Common ...

  • RETRANSMISSION: Innocan Pharma Announces up to $10 Million Public Offering of Units
    Newsfile

    RETRANSMISSION: Innocan Pharma Announces up to $10 Million Public Offering of Units

    Toronto, Ontario--(Newsfile Corp. - May 12, 2020) - (reissued May 12, 2020) Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it has filed and been receipted for a preliminary short form prospectus with the securities regulatory authorities in all provinces of Canada (except Quebec) in connection with a marketed public offering (the "Offering") of units of the Company ("Units") for gross proceeds of up to ...

  • Innocan Pharma Announces up to $10 Million Public Offering of Units
    Newsfile

    Innocan Pharma Announces up to $10 Million Public Offering of Units

    Toronto, Ontario--(Newsfile Corp. - May 11, 2020) - Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan") is pleased to announce that it has filed and been receipted for a preliminary short form prospectus with the securities regulatory authorities in all provinces of Canada (except Quebec) in connection with a marketed public offering (the "Offering") of units of the Company ("Units") for gross proceeds of up to $10,000,000. The Offering is being ...

  • InnoCan Announces Appointment of Professor Daniel Offen, Scientific Advisory Director
    Newsfile

    InnoCan Announces Appointment of Professor Daniel Offen, Scientific Advisory Director

    Herzeliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 1, 2020) - InnoCan Pharma Corporation (CSE: INNO) ("InnoCan" or the "Company") announced that its wholly-owned subsidiary, InnoCan Pharma Ltd. of Herzliya Israel, has announced today that the Management of InnoCan has appointed Prof. Daniel Offen, of the Sackler School of Medicine, Sagol School of Neuroscience at Tel Aviv University, to its Scientific Advisory Committee.Recently, on April 17th InnoCan announced that its wholly-owned subsidiary, ...

  • InnoCan to Develop a New Lines of CBD Products for Tamar Technologies
    Newsfile

    InnoCan to Develop a New Lines of CBD Products for Tamar Technologies

    Herzeliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 28, 2020) - InnoCan Pharma Corporation (CSE: INNO) (FSE: IP4) ("InnoCan" or the "Company") announced that its major shareholder Tamar Technologies Ltd (formerly Solsken Ltd) ("Tamar"), has notified InnoCan of its intention to exercise its rights to license InnoCan's formulations and know-how for existing CBD products and new CBD formulations pursuant to the Cooperation Agreement between Tamar and InnoCan's wholly-owned subsidiary, InnoCan Pharma Ltd. dated ...

  • InnoCan Pharma Collaborates with Tel Aviv University to Develop a New Revolutionary Approach to Treat the COVID-19 Corona Virus with Exosomes-Loaded CBD
    Newsfile

    InnoCan Pharma Collaborates with Tel Aviv University to Develop a New Revolutionary Approach to Treat the COVID-19 Corona Virus with Exosomes-Loaded CBD

    Herzeliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 17, 2020) - InnoCan Pharma Corporation (CSE: INNO) ("InnoCan" or the "Company") announced that its wholly-owned subsidiary, InnoCan Pharma Ltd. of Herzliya Israel, has entered into a sponsored research agreement dated April 17, 2020 (the "Research Agreement") with Ramot at Tel Aviv University ("Ramot") to collaborate with Tel Aviv university to develop a novel, revolutionary approach to treat COVID-19 by using Cannabidiol (CBD) loaded Exosomes ...

  • InnoCan Provides Update and Summary About Its Corporate Progress as Its First Products Prepare to Enter the Commercial Marketplace
    Newsfile

    InnoCan Provides Update and Summary About Its Corporate Progress as Its First Products Prepare to Enter the Commercial Marketplace

    Calgary, Alberta--(Newsfile Corp. - February 11, 2020) - InnoCan Pharma Corporation (CSE: INNO) ("InnoCan" or the "Company"), today provided an update and summary of its activities and achievements as a public company during its first five months. All supporting documents and references can be found at www.sedar.comIris Bincovich, InnoCan's CEO, said, "InnoCan has made significant strides in less than two quarters as a public company. We are successfully executing our business plan ...

  • InnoCan Pharma Announces Patent Application for Novel Hemorrhoid Treatment
    Newsfile

    InnoCan Pharma Announces Patent Application for Novel Hemorrhoid Treatment

    Herzeliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 5, 2020) - InnoCan Pharma Corporation (CSE: INNO) ("InnoCan" or the "Company") announced today the filing of a new patent application for a cannabis-based formula targeting the pain, swelling and inflammation associated with hemorrhoids.Hemorrhoids are the fourth leading gastrointestinal disease diagnosed in outpatient settings. This accounts for approximately 3.3 million ambulatory care visits. Furthermore 10 million cases per year are self-reported in the U.S., ...

  • ACCESSWIRE

    InnoCan Signs its First Distribution Agreement with "Active Therapeutics" for InnoCan's CBD Derma Cosmetics products in the United Kingdom and Ireland

    HERZLIYA, ISRAEL and CALGARY, AB / ACCESSWIRE / January 28, 2020 / InnoCan Pharma Corporation ("InnoCan" or the "Company") (INNO.CN) announced today that it has signed a distribution agreement with Active Therapeutics Ltd ("Active Therapeutics"), part of Natural Resources (NW) LTD ("Natural Resources") of Lancashire, United Kingdom to distribute InnoCan's cutting edge scientifically CBD based Derma Cosmetic products in the UK and Ireland markets. Active Therapeutics Ltd. has vast experience in pharmaceuticals and healthcare including the brand portfolios of Merck, GSK, Astra Zeneca, 3M, and STADA.

  • ACCESSWIRE

    InnoCan Announces Appointment of Prominent Healthcare Executive, Peter Bloch as a Director

    CALGARY, AB and TEL AVIV, ISRAEL / ACCESSWIRE / January 23, 2020 / InnoCan Pharma ("InnoCan" or the "Company") (INNO:CSE) announced today that it is has added Peter Bloch to its Board of Directors. Mr. Bloch is a Chartered Accountant with an extensive record of entrepreneurial and executive successes. Mr. Bloch is currently the CEO of Bresotec Inc., a Medical device company developing and commercializing easy to use and accurate technologies for the diagnosis and treatment of sleep apnea and related health conditions through acoustic analysis.

  • ACCESSWIRE

    InnoCan Announces Successful Research Study Advancing Its Development of Cannabidiol Targeted Injection Delivery Platform

    CALGARY, ALBERTA and TEL AVIV, ISRAEL / ACCESSWIRE / January 13, 2020 / InnoCan Pharma Corporation ("InnoCan" or the "Company") (INNO:CSE) announced today that test results of its unique cannabidiol (CBD) loaded liposomal platform technology developed under the Company's previously announced funded research agreement (the "Yissum Agreement") with Yissum Research and Development Company ("Yissum"), the commercial arm of Hebrew University (Jerusalem) demonstrated high loading of CBD, having the potential of a new way of administration by injection. High loading of CBD was achieved.

  • Canadian Securities Exchange Attracts First Israeli Company Listings
    Newsfile

    Canadian Securities Exchange Attracts First Israeli Company Listings

    IM Cannabis becomes third Israeli cannabis listing in past six weeks Toronto, Ontario--(Newsfile Corp. - November 5, 2019) - The Canadian Securities Exchange ("CSE" or "the Exchange") welcomes the listing of three Israel-based companies on the Exchange over the past six weeks: InnoCan Pharma Corp. (CSE: INNO), Isracann Biosciences Inc. (CSE: IPOT), and IM Cannabis Corp. (CSE: IMCC), which began trading today. ...

  • ACCESSWIRE

    InnoCan Pharma Plans to Enter CBD Beauty Market with Launch of InnoCan Branded Cosmetic Products in H1/20

    InnoCan Pharma Plans to Enter CBD Beauty Market with Launch of InnoCan Branded Cosmetic Products in H1/20 CALGARY, ALBERTA and TEL AVIV, ISRAEL / ACCESSWIRE / October 21, 2019 / InnoCan Pharma (" ...

  • Canadian Securities Exchange Reports Strong Trading Activity, Listings Growth and Other Milestones in Third Quarter of 2019
    Newsfile

    Canadian Securities Exchange Reports Strong Trading Activity, Listings Growth and Other Milestones in Third Quarter of 2019

    Quarter highlighted by listing of 500th issuer and opening of CSE Media Centre Toronto, Ontario--(Newsfile Corp. - October 16, 2019) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced performance and operating highlights for the third quarter ("Q3 2019") and nine months ("YTD 2019") ended September 30, 2019. The CSE achieved key milestones during the quarter, including the launch of the CSE Media Centre in Toronto and the listing of its 500th ...